Osmotic drugs in the treatment of cochlear disorders: a clinical and experimental study.
On the grounds of positive results obtained with Meniere's patients, agents such as glycerol and mannitol have been included in the therapeutical protocol of other cochlear disorders presenting with hearing loss either of sudden onset, but not observed at an early stage, or accompanied by tinnitus and aural pressure. Intravenous infusions of either 10% glycerol or 18% mannitol were given to selected patients 3 to 6 times with a time interval of 1 to 3 days. Hearing loss, tinnitus and aural pressure were evaluated as improved, unchanged or worsened. In 33% of the glycerol group and 23.8% of the mannitol group we observed hearing threshold improvement, while aural fullness improved in 45% of the glycerol and 56.2% of the mannitol groups, and tinnitus was only relieved in 13.1% of the glycerol and 5.8% of the mannitol group. A parallel experimental study was carried out on guinea-pigs in order to shed light on the effects of mannitol and glycerol on the inner ear. Cochlear blood flow was measured with a laser Doppler flowmeter at the level of the basal turn of the cochlear lateral wall, both in normal and hydropic guinea-pigs, before and after osmotic intraperitoneal infusion. Basal values in the normal cochlea were much higher than in the hydropic one, and both mannitol and glycerol markedly influenced the local blood flow in the normal cochlea, giving few or no changes in the hydropic one.
Filipo
R
R
Department of Otolaryngology, University of Rome La Sapienza, Italy.
Barbara
M
M
Cordier
A
A
Mafera
B
B
Romeo
R
R
Attanasio
G
G
Mancini
P
P
Marzetti
A
A
D000818:Animals; D001309:Auditory Threshold; D003051:Cochlea / Q000098:blood supply; D015834:Cochlear Diseases / Q000188:drug therapy*; D018159:Endolymphatic Hydrops / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D005990:Glycerol / Q000008:administration & dosage / Q000627:therapeutic use*; D006168:Guinea Pigs; D006309:Hearing; D006319:Hearing Loss, Sensorineural / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007262:Infusions, Intravenous; D017078:Laser-Doppler Flowmetry; D008353:Mannitol / Q000008:administration & dosage / Q000627:therapeutic use*; D013316:Stria Vascularis / Q000473:pathology; D014012:Tinnitus / Q000628:therapy
D008353:Mannitol; D005990:Glycerol